Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Aerie Pharmaceuticals, Inc.
Oklahoma City, OK (May 4, 2015) – On April 29, 2015, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Aerie Pharmaceuticals, Inc. (NASDAQ: AERI). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 6, 2014 through April 23, 2015. More specifically, this litigation was filed because on April 23, 2015, the Company issued a press release announcing the results of its first Phase 3 registration trial for RhopressaTM. According to the release, “[T]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.” On this news, the Company’s shares declined to close at $12.87.
Plaintiff seeks to recover damages on behalf of all Aerie Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, June 29, 2015 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
To join this class action, click hereto obtain an investor certification. Once complete, please email this form to firstname.lastname@example.org, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.
Posted on Mon, May 4, 2015
by Robin Hester filed under